Creating a Closed-Process, Semi-Automated Workflow for Human MSC Expansion, Harvest, and Final Fill

RECORDED WEbinar

It’s difficult to scale cell and gene therapy production using all-in-one processing systems. That’s because the budget level and personnel required may make it cost-prohibitive to increase capacity. In this webinar, we’ll discuss the benefits of a decentralized manufacturing strategy. Using a real-life case study, we’ll demonstrate how this approach can help users scale from lab to commercial levels. 

• Creation and use of semi-automated modular workflows
• When to deploy off-the-shelf consumables
• Closed-system bone-marrow derived mesenchymal stem cell growth and recovery

Speakers:

Kyle Harvey, Doctor of Pharmacy, Ph.D.

Research scientist in regenerative medicine, MED Institute, Inc.

Kyle Harvey is a research scientist for the regenerative medicine team at MED Institute. Kyle graduated from Purdue with a Doctor of Pharmacy degree in 2016. He then continued his education at Purdue to pursue a doctorate in molecular pharmacology, which he completed in the fall of 2022. He joined the MED Institute team in the fall of 2022 and leads the regenerative medicine team.

Donnie Beers

LS Applications leader, cell and gene therapy, Entegris, Inc.

Donnie has 15 years’ experience in single-use and automation technology. He joined Entegris in 2019 as senior product manager and has since taken the lead in facilitating cell and gene therapy applications. He has previously held roles in engineering management, project management, and manufacturing within a Current Good Manufacturing Practice environment. Donnie earned his Bachelor of Science in Biochemistry from University of Wisconsin–Madison.